FAM19A5 (TAFA5) is a highly conserved secreted protein predominantly expressed in the central nervous system (CNS) and active in fibrotic tissues. Emerging as a critical regulator of neurogenesis, wound healing, and tissue fibrosis, FAM19A5 is a high-value therapeutic target for neurodegenerative diseases, traumatic brain injury (TBI), and multi-organ fibrotic conditions. Developing therapeutics against this secreted chemokine-like protein requires high-purity antigens with native post-translational modifications and precise conformation to generate highly selective blocking antibodies.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FAM19A5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FAM19A5 Recombinant Protein (HEK293 expressed, C-Fc or His Tag, High Purity >95%, Endotoxin Controlled <1.0 EU/μg, Sequence Verified) | View FAM19A5 Products |
| Gene Delivery | FAM19A5 Lentivirus Particles / Promise-ORF Clone (Full-length ORF for stable cell line generation) | View FAM19A5 Products |
| Benchmark Ab | Anti-FAM19A5 Recombinant Monoclonal Antibody (Sequence derived from clinical benchmark NS101) | View FAM19A5 Products |
| Validator | FAM19A5 siRNA Set (Target-specific gene knockdown validation) | View FAM19A5 Products |
| Related Target A | NRXN1 (Neurexin-1) Recombinant Protein & Lentivirus (Key synaptic receptor interacting with FAM19A5 in CNS regeneration pathways) | View NRXN1 Products |
| Related Target B | S1PR2 (Sphingosine-1-Phosphate Receptor 2) Recombinant Protein & Lentivirus (GPCR involved in FAM19A5-mediated fibrotic pathways) | View S1PR2 Products |
| Related Target C | TGFB1 (Transforming Growth Factor Beta 1) Recombinant Protein (Synergistic master regulator of tissue fibrosis) | View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation in preclinical models | Human, mouse, and cynomolgus ortholog proteins available with >95% purity and verified theoretical MW |
| Subfamily counter-screening (avoiding TAFA1-4 off-target binding) | Full panel of recombinant TAFA family proteins (TAFA1, TAFA2, TAFA3, TAFA4) for specificity ELISA/SPR assays |
| Lack of positive control for blocking assays | Clinical-grade Benchmark Antibody (biosimilar of NS101) for assay baseline calibration |
| False positive signaling in cell-based assays | Sequence-verified siRNA knockdown validation tools included |
Live FAM19A5/TAFA5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FAM19A5 therapeutics is intensifying, with major players shifting focus from traditional systemic monoclonal antibodies to targeted neuro-restorative and anti-fibrotic formulations. As first-generation therapies reach the clinic, the next wave of R&D is targeting localized delivery and dual-targeting bispecific antibodies to overcome the blood-brain barrier (BBB) and minimize systemic clearing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Neuracle Science, HLB, GC Biopharma | Traumatic Brain Injury (TBI), Spinal Cord Injury, Liver/Pulmonary Fibrosis | Receptor-ligand blocking assays (Requires high-purity FAM19A5 and NRXN1/S1PR2 proteins) |
| Bispecific Antibody / BBB shuttle | Emerging Biotech, Academic Institutes | Alzheimer's Disease, Stroke recovery | Affinity determination and transcytosis validation (Requires biotinylated/tagged target proteins) |
| Small Molecule / Peptide Inhibitors | Discovery Stage Programs | Myocardial Infarction, Fibrotic Diseases | High-throughput screening (HTS) and target-binding verification (Requires stable HEK293 expressed FAM19A5) |